# A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

> **NCT02881138** · PHASE1 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RC48-ADC

## Key facts

- **NCT ID:** NCT02881138
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-07-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02881138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02881138, "A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02881138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*